Please assess the completion status of the following clinical trial:

Trial Title: 20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) schizophrenia~* Total score on the PANSS Marder Negative Symptom Factor Scale (NSFS) ≥ 20~* Total score on the PANSS Marder Positive Symptom Factor Scale (PSFS) ≤ 30~* Receiving stable antipsychotic therapy for at least 8 weeks prior to screening~* Receiving a stable dose of other psychotropic agents for at least 8 weeks prior to screening~* Subject has had a stable residence or living arrangement for at least 8 weeks prior to screening and the residence or living arrangement is not anticipated to change for the duration of the study~* The subject or subject's legally acceptable representative has provided informed consent.~Exclusion Criteria:~* Current schizoaffective or bipolar disorder, panic disorder, obsessive compulsive disorder, evidence of mental retardation by history or clinical examination or known premorbid IQ ≤ 70~* Clinically significant suicidal ideation or suicide attempts, assaultive behavior or marked changes in mood within the 8 weeks prior to screening, or currently endorsing suicidal ideation in clinical exam~* Substance abuse (with the exception of nicotine or caffeine abuse) within the 8 weeks prior to screening, or during screening~* Substance dependence (with the exception of nicotine or caffeine dependence) within the 6 months prior to screening, or during screening~* Planning to initiate a smoking cessation therapy or otherwise substantially modify nicotine use during the study~* Positive urine drug test for substances of abuse (with the exception of positive screens for prescribed agents such as benzodiazepines).~* Other criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- AMG 747 - Dose 1 (Type: EXPERIMENTAL): None
- AMG 747 - Dose 2 (Type: EXPERIMENTAL): None
- AMG 747 - Dose 3 (Type: EXPERIMENTAL): None
- Placebo Comparator (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).